Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

U.S. Merck Looks For Developing Country Markets

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck's second-quarter results demonstrate the risks and rewards of becoming less U.S.-centric. Emerging markets expansion and new product launches outside of the U.S. drove growth, but EU price cuts dampened revenues and profits.

You may also be interested in...



Hot Opportunities In The African Emerging Markets - A Look At South Africa (Part 1 of 2)

Although the fast-growing South African pharmaceutical market is dominated by local generic firms, multinational pharma companies are also seeing significant growth through new initiatives and product launches, said investment firm Credit Suisse in a September report based on IMS Health data

Western Companies' Perspectives On Emerging Markets: Execution Trumps Strategy - PharmAsia Summit

SAN FRANCISCO - Western companies expanding in emerging markets are likely to distinguish themselves from competitors by successful execution and understanding of local markets, more so than by broad strategic differences, according to participants on a panel on Big Pharma perspectives on emerging markets at Elsevier Business Intelligence's PharmAsia Summit, held Oct. 26 in San Francisco

Strong Diabetes Franchise Growth Highlights Solid Third Quarter For Merck

Three new product launches also were among the bright spots in a quarter in which the pharma posted net income of $342 million.

Related Content

Topics

UsernamePublicRestriction

Register

PS070987

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel